<DOC>
	<DOCNO>NCT02453386</DOCNO>
	<brief_summary>Phase 3 , international , multicenter , randomize , double-blind , placebo-controlled , parallel-group , 3-arm safety efficacy study ( Part A ) open-label phase ( Part B ) .</brief_summary>
	<brief_title>Safety Efficacy Study Tozadenant Treat End Dose Wearing Off Parkinson 's Patients Using Levodopa</brief_title>
	<detailed_description>During Part A , patient participate 30 week , include Screening Period 1 ≤ 6 week , follow Baseline Visit 24 week double-blind treatment : - Screening Period : 1 - 6 week . - Double-Blind Treatment Period : 24 week . After completion Part A , patient continue Part B additional 56 week : - Open-Label Treatment Period : 52 week . - Post-Treatment Safety Follow Up : 4 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patient understand study requirement give his/her write informed consent Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve consent form . Parkinson 's disease diagnosis consistent UK Parkinson 's Disease Society Brain Bank Diagnostic criterion Minimum 3 year since diagnosis . Meet Hoehn Yahr PD stage Good response levodopa Stable regimen antiPD medication Patients must take levodopacontaining antiPD medication continuously least previous 12 month Patient document minimum amount Off time . If childbearing potential ( male female ) must use acceptable method contraception Previous tozadenant study participation Current recent participation another study . Secondary atypical parkinsonism Neurosurgical intervention PD Patient take apomorphine , budipine , istradefylline , tolcapone , DUOPA™/Duodopa® Treatment exclude medication Untreated uncontrolled hyperthyroidism hypothyroidism Clinically significant outofrange laboratory MMSE range Current episode major depression ( stable treatment depression permit ) . Recent suicide attempt suicidal ideation type 4 type 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Women lactate pregnant Hypersensitivity component tozadenant excipients Abnormal finding physical neurological examination , medical history would make patient unsuitable study History hepatitis cholangitis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Motor fluctuation</keyword>
	<keyword>Off time</keyword>
	<keyword>On time</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>